MS and the Future

From: Extropian Agro Forestry Ventures Inc. (megao@sk.sympatico.ca)
Date: Mon Jun 10 2002 - 21:55:16 MDT


Subject:
             [Fwd: [Fwd: [Fwd: Lipitor interactions with
nutraceuticals????]]]
        Date:
             Wed, 01 May 2002 21:22:06 -0500
       From:
             "Extropian Agro Forestry Ventures Inc."
<megao@sk.sympatico.ca>
 Organization:
             EAV Inc.
         To:
             steinman@stanford.edu

Hi:
I went the hard way to locate you... by sending an email to someone
whose had changed I was redirected to the university directory where I
immediately found you...crude but effective.

I hope you have a copy of the FASEB 2002 paper that you could fwd by e
or snail mail.

Morris Johnson.

      Subject:
             [Fwd: [Fwd: Lipitor interactions with nutraceuticals????]]
        Date:
             Wed, 01 May 2002 21:11:38 -0500
       From:
             "Extropian Agro Forestry Ventures Inc."
<megao@sk.sympatico.ca>
 Organization:
             EAV Inc.
         To:
             sawsan@stanford.edu

Hi: I am looking for a copy of your paper as presented at FASEB April
23.
 If you have a something you could e-mail i'd be thrilled. As you see
from the attached original message I am trying to ascertain as well
some indication of other interactions which might bar upon the
activity you are investigating.

Morris Johnson
306-447-4944

      Subject:
             [Fwd: Lipitor interactions with nutraceuticals????]
        Date:
             Wed, 01 May 2002 20:55:53 -0500
       From:
             "Extropian Agro Forestry Ventures Inc."
<megao@sk.sympatico.ca>
 Organization:
             EAV Inc.
         To:
             gchin@leland.stanford.edu, colaiaco@cmgm.stanford.edu,
cdarby@stanford.edu,
             eizinger@stanford.edu, mbgoodmn@stanford.edu,
mbgoodmn@stanford.edu,
             hillers@stanford.edu, kelly@cmgm.stanford.edu,
kim@cmgm.stanford.edu,
             jdlieb@genome.stanford.edu, flygirl1@stanford.edu,
kirthi@stanford.edu,
             gillians@stanford.edu, mwtan@stanford.edu,
villen@cmgm.stanford.edu,

Hi- I am looking for the e-mail or phone number for one or more of the

authors of the following paper:
If any of you can re-direct me I'd appreciate it. I'm including a CC of

the original inquiry made to the conference organizers FYI.

Thanks, in advance

Morris Johnson
306-447-4944

The HMG-CoA Reductase Inhibitor, Atorvastatin , Promotes a Th2 bias and
Reversal
of Paralysis in Chronic Relapsing Experimental Autoimmune
Encephalomyelitis
Sawsan Youssef 1 , Olaf Stuve 2 , Pedro J Ruiz 1 , Lawrence Steinman 1 ,

Scott S Zamvil 2 .
1 Neurology and Neurological Sciences, Stanford University, Beckman
Center for Molecular
Sciences, Stanford University, CA 94305, 2 Neurology, University of
California San
Francisco, San Francisco, CA
Recent investigations have indicated that HMG-CoA reductase inhibitors
("statins"),
cholesterol lowering agents, have immunomodulatory properties. In this
study we
examined whether Atorvastatin (LipitorŪ) could inhibit the
proinflammatory response in
experimental autoimmune encephalomyelitis (EAE), a Th1 mediated central
nervous system
(CNS) demyelinating disease that serves as a model for multiple
sclerosis (MS). Daily oral
administration of Atorvastatin initiated at the onset of MOG
p35-55-induced EAE in
C57BL/6 mice, reversed paralysis in chronic EAE in those mice.
Atorvstatin also
ameliorated the relapses in SJL/J mice when given after the acute attack

in relapsing-remitting
EAE induced by PLP p139-151. Histological evaluation of brains and
spinal
cords, taken from the Atorvastatin treated mice, showed significant
reduction in both the
number of the perivascular lesions as well as the extent of infiltration

in those lesions. In
Atorvastatin-treated mice CNS autoantigen-specific proliferative T cell
responses were
reduced in a dose dependent manner. Interestingly, Atorvastatin
treatment was associated
with decreased INF-gamma secretion and increased IL-4 and IL-10
secretion by CNS
autoantigen-specific T cells. Thus, Atorvastatin treatment promoted a
Th2 bias. Our results
demonstrate that Atorvastatin is effective immunomodulatory agent for
the treatment of
murine EAE, and suggest that statins may have a role in treatment of MS
and other
autoimmune diseases.

     Subject:
            Re: Lipitor interactions with nutraceuticals????
       Date:
            Wed, 01 May 2002 21:05:22 -0400
      From:
            eb2press <eb2press@bellsouth.net>
        To:
            "Extropian Agro Forestry Ventures Inc."
<megao@sk.sympatico.ca>
 References:
            1



This archive was generated by hypermail 2.1.5 : Sat Nov 02 2002 - 09:14:43 MST